drug · protein
EYLEA HD
Marketedupdated 6mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $9.4B
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval44 co-mentions · 15 sources
- drugEylea32 co-mentions · 15 sources
- drugYESAFILI18 co-mentions · 7 sources
- drugaflibercept biosimilar17 co-mentions · 10 sources
- drugOPUVIZ8 co-mentions · 4 sources
- drugENZEEVU6 co-mentions · 3 sources
- companySamsung Bioepis Co Ltd4 co-mentions · 4 sources
- companyBiocon Biologics Ltd4 co-mentions · 2 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with 16 approved and 39 investigational indications.
indications
investigational
Diabetic Macular Edema
targets
Placenta growth factorVascular endothelial growth factor A, long form
all catalysts(5)
approval · 5
Aug 18, 2023
approval
$REGN920.69-0.19%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Dec 14, 2023
approval
$REGN920.69-0.19%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Oct 10, 2024
approval
$REGN920.69-0.19%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Nov 19, 2025
approval
$REGN920.69-0.19%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Apr 2, 2026
approval
$REGN920.69-0.19%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Trials studying EYLEA HD
- phase3A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)
- phase3A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
- phase2RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
- phase3A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
- phase2A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
- —An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
- phase3CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
- phase3Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
News(10)
- With FDA nod, Regeneron brings an RNAi drug to autoimmune diseaseThe product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.biopharma_dive · 2d ago
- J&J bets $2.2B on Ollin’s vision loss drugThe deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.biopharma_dive · 5d ago
- J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecificJohnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.fiercebiotech · 5d ago
- Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilienceAstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.biopharma_dive · 19d ago
- Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deckRegeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…biospace · 22d ago
- EyePoint will halve workforce, end pivotal wet AMD trials early following second failEyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shiftin…biospace · 1mo ago
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingThe latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.biopharma_dive · 1mo ago
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 1mo ago
- Kodiak skyrockets on positive study data for 2 eye drugsThe Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.biopharma_dive · 1mo ago
- Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitorKodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet a…endpoints · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that